Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, PR China.
Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, PR China.
Biosens Bioelectron. 2025 Jan 15;268:116926. doi: 10.1016/j.bios.2024.116926. Epub 2024 Nov 9.
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by the loss of dopaminergic neurons and the consequent decline in motor and cognitive functions. The primary therapeutic agent levodopa necessitates precise dosing due to its narrow therapeutic window and complex pharmacokinetics. This study presents the development of a novel CuCoFe-LDHzyme-based sweat sensor for real-time monitoring of levodopa concentration in PD patients. Employing differential pulse voltammetry (DPV) technique, the sensor demonstrates high sensitivity and selectivity, achieving a detection limit of 28.1 nM. The sensor's design allows for non-invasive, continuous monitoring, significantly enhancing patient convenience compared to traditional blood sampling methods. Through pH correction, precise quantification of levodopa in sweat is accomplished, and a strong correlation (Pearson coefficient = 0.833) with blood levodopa levels is established. The pharmacokinetic profile of levodopa is reconstructed in real-time, offering a promising tool for optimizing PD treatment regimens. This study highlights the potential of CuCoFe-LDHzyme sensors to advance personalized treatment strategies, aiming to improve the quality of life for PD patients by providing clinicians with real-time data for medication adjustments.
帕金森病（PD）是一种进行性神经退行性疾病，其特征是多巴胺能神经元丧失，运动和认知功能随之下降。由于其治疗窗口狭窄和复杂的药代动力学，主要治疗药物左旋多巴需要精确的剂量。本研究提出了一种基于 CuCoFe-LDHzyme 的新型汗液传感器，用于实时监测 PD 患者的左旋多巴浓度。该传感器采用差分脉冲伏安法（DPV）技术，具有高灵敏度和选择性，检测限低至 28.1 nM。该传感器的设计允许进行非侵入性、连续监测，与传统的血液采样方法相比，显著提高了患者的便利性。通过 pH 校正，可以精确地定量汗液中的左旋多巴，并与血液中的左旋多巴水平建立了很强的相关性（Pearson 系数=0.833）。实时重建了左旋多巴的药代动力学特征，为优化 PD 治疗方案提供了有前途的工具。本研究强调了 CuCoFe-LDHzyme 传感器在推进个性化治疗策略方面的潜力，旨在通过为临床医生提供药物调整的实时数据，提高 PD 患者的生活质量。
